newsfilter
← Latest News
GlobeNewswire·

RenovoRx CEO, Shaun Bagai, to Present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 on June 23rd

  • RenovoRx CEO Shaun Bagai will present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 on June 23, 2026, at 12:30 P.M. ET.
  • The presentation will cover RenovoRx's record first quarter 2026 revenue driven by demand for the RenovoCath drug-delivery device.
  • RenovoRx expects to complete enrollment in its Phase III TIGeR-PaC clinical trial by the end of June 2026, with final data anticipated in mid-to-late 2027.
  • The TIGeR-PaC trial evaluates intra-arterial gemcitabine (IAG) delivered via RenovoCath for locally advanced pancreatic cancer.
  • The FDA granted Orphan Drug Designation for oxaliplatin for pancreatic cancer, marking RenovoRx's second such designation for pancreatic cancer & third overall.
  • RenovoRx is advancing investigator-initiated trials & a post-marketing registry study to generate data for its TAMP platform.
  • RenovoRx generated approximately $1.1 million in RenovoCath sales in 2025 & a record $563,000 in sales during Q1 2026.
  • RenovoRx is expanding orders to high-volume National Cancer Institute-designated cancer centers.
  • RenovoCath is an FDA-cleared device for isolating blood flow & delivering therapeutic agents to peripheral vascular sites.
  • Forward-looking statements regarding clinical trial timelines & commercialization are subject to risks & uncertainties.